Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AKTS vs SPRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SPRO Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–1 Matrix Metrics)

SPRO Overall Winner 6-Pillar Tally: AKTS 0 – 6 SPRO Matrix Metrics: AKTS 1 – 8 SPRO

As of Nov 16, 2026, Spero Therapeutics, Inc. (SPRO) is the stronger overall head-to-head candidate over AKTS (AKTS) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTS carries a Unified Composite Score of 30.6/100 (SELL) at $16.49 (N/M Forward P/E, N/A operating margin), whereas SPRO carries 47.8/100 (HOLD) at $0.90 (N/M Forward P/E, 14.1% operating margin).

  • Technical & Structure Timing Caution: AKTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.1); meanwhile SPRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKTS vs SPRO
AKTS US Equity
AKTS
Institutional Equity
$16.49
-0.78% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.36β · 66% Vol
Unified Composite Score
30.6 / 100 SELL
Tech 20.0 Fund 36.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $16.12 · SMA50: $18.33
SPRO NASDAQ Head-to-Head Winner
Spero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.90
-9.97% 1D
Market Cap $58.8M
TTM Revenue $47M
Forward P/E N/M
Beta / 30D Vol 1.70β · 65% Vol
Unified Composite Score
47.8 / 100 HOLD
Tech 39.0 Fund 53.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $1.07 · SMA50: $1.13

6-Pillar Scorecard Institutional Category Breakdown (AKTS 0 – 6 SPRO)

Columns: Metric · AKTS · SPRO
1. Valuation Multiples SPRO
Forward P/E N/M N/M
Trailing P/E N/M 7.2x
PEG Ratio N/M N/M
EV / Revenue N/M 0.2x
2. Growth & Scale SPRO
Revenue Growth (YoY) N/A -95.6%
Earnings Growth (YoY) N/A +75.3%
TTM Revenue (USD) N/A $47M
Market Cap N/A $58.8M
3. Profitability & Quality SPRO
Gross Margin N/A 56.3%
Operating Margin N/A 14.1%
Net Profit Margin N/A 15.7%
Return on Equity (ROE) N/A 19.2%
4. Balance Sheet & Cash Flow SPRO
Cash Generation (TTM) N/A $20M
Cash Flow Margin N/A 41.7%
Net Cash / Leverage N/A ROE $49M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SPRO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 114.8% (24th %ile)
Put/Call OI Skew N/A 3.16x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat SPRO
OpEx & R&D Intensity N/A 42.2% of Rev ($20M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKTS (1) vs SPRO (8)
Institutional Metric AKTS SPRO Criterion Row Edge
Market Capitalization
Scale
N/A $58.8M Larger Scale SPRO
Trailing P/E Ratio
Valuation
N/M 7.2x Lower Multiple SPRO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -95.6% Higher Growth SPRO
Operating Margin (TTM)
Profitability
N/A 14.1% Higher Margin SPRO
Net Profit Margin
Profitability
N/A 15.7% Higher Margin SPRO
Return on Equity (ROE)
Capital Efficiency
N/A 19.2% Higher ROE SPRO
52-Week Range Position
Momentum
12% ($14–$34) 0% ($1–$3) Stronger Trend AKTS
Beta / 30D Volatility
Risk Regime
1.36β · 66% Vol 1.70β · 65% Vol Lower Realized Risk SPRO
Unified Institutional Score
Composite Signal
30.6 / 100 (SELL) 47.8 / 100 (HOLD) Higher Composite SPRO
Trailing 12M Revenue (USD)
Operating Scale
N/A $47M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 56.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $20M ($49M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AKTS +27.66 pp
AKTS: +9.5% · SPRO: -18.16%
3M Horizon SPRO +9.06 pp
AKTS: -34.04% · SPRO: -24.98%
6M Horizon AKTS +53.72 pp
AKTS: -11.39% · SPRO: -65.11%
1Y Horizon AKTS +38.32 pp
AKTS: -26.38% · SPRO: -64.7%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKTS vs SPRO. Trailing 12-month operating profitability (AKTS N/A vs SPRO 14.1%) and valuation multiples (AKTS N/M vs SPRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AKTS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SPRO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$47M
Gross Margin56.3%
Op. Margin14.1%
ROE / Fwd P/E19.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKTS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SPRO BREAKDOWN
120d in phase · OBV NEUTRAL
Current IV 114.8%
IV Percentile 24th %ile
Put/Call OI Skew 3.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SPRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKTS Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SPRO Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $58.8M market capitalization and 14.1% operating margin.
OpEx & R&D Reinvestment 42.2% of Rev ($20M)
90D Engineering Disclosures 0 Published

Investor FAQ AKTS vs SPRO Key Questions & Quantitative Answers

As of Nov 16, 2026, Spero Therapeutics, Inc. (SPRO) is the stronger overall head-to-head candidate over AKTS (AKTS) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTS carries a Unified Composite Score of 30.6/100 (SELL) at $16.49 (N/M Forward P/E, N/A operating margin), whereas SPRO carries 47.8/100 (HOLD) at $0.90 (N/M Forward P/E, 14.1% operating margin). Technical & Structure Timing Caution: AKTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.1); meanwhile SPRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SPRO leads the Growth & Scale pillar: AKTS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SPRO at -95.6% YoY revenue growth and +75.3% YoY earnings growth on $47M TTM revenue (56.3% gross margin, 14.1% operating margin). On trailing 12-month operating scale, AKTS generates N/A in USD-normalized revenue versus $47M for SPRO. In operating R&D and SG&A reinvestment, AKTS deploys N/A (0 90-day corporate R&D disclosures) versus 42.2% of Rev ($20M) (0 disclosures) for SPRO.

SPRO screens cheaper on headline valuation multiples. AKTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SPRO trades at N/M Forward P/E, 7.2x Trailing P/E, N/M PEG, and 0.2x EV/Revenue (41.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKTS (N/A ROE) versus SPRO (19.2% ROE) capital efficiency.

In options market volatility and institutional positioning, AKTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 66% Vol realized risk). By comparison, SPRO carries 114.8% implied volatility (24th %ile, Compressed (<25th %ile)), a 3.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.